

# The Constituents of the Stems of *Cissus assamica* and Their Bioactivities

Yu-Yi Chan <sup>1</sup>, Chiu-Yuan Wang <sup>1</sup>, Tsong-Long Hwang <sup>2,3,4</sup>, Shin-Hun Juang <sup>5</sup>, Hsin-Yi Hung <sup>6</sup>, Ping-Chung Kuo <sup>6</sup>, Po-Jen Chen <sup>7</sup> and Tian-Shung Wu <sup>5,6,\*</sup>

<sup>1</sup> Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan 71005, Taiwan; yuyichan@stust.edu.tw (Y.-Y.C.); m98h0104@gmail.com (C.-Y.W.)

<sup>2</sup> Graduate Institute of Natural Products, School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan; htl@mail.cgu.edu.tw

<sup>3</sup> Research Center for Chinese Herbal Medicine, Research Center for Food and Cosmetic Safety, Graduate Institute of Health Industry Technology, College of Human Ecology, Chang Gung University of Science and Technology, Taoyuan 333, Taiwan

<sup>4</sup> Department of Anesthesiology, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan

<sup>5</sup> Department of Pharmacy, Tajen University, Pingtung 90741, Taiwan; paul.juang@gmail.com

<sup>6</sup> School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan; z10308005@email.ncku.edu.tw (H.-Y.H.); z10502016@email.ncku.edu.tw (P.-C.K.);

<sup>7</sup> Department of Cosmetic Science, Providence University, Taichung 433, Taiwan; litlep@hotmail.com

\* Correspondence: tswu@mail.ncku.edu.tw; Tel.: +886-6-2757575 (ext. 65333)

Received: 24 September 2018; Accepted: 26 October 2018; Published: 28 October 2018

**Abstract:** Fifty-five compounds were isolated from the fresh stems of *Cissus assamica*, including 14 benzenoids, 11 triterpenes, nine steroids, five tocopherols, five chlorophylls, four flavonoids, two benzoquinones, two tannins, and three other compounds. Their structures were constructed by 1D and 2D nuclear magnetic resonance (NMR) and mass spectral data, and were also identified by a comparison of their spectral data with those reported in the literature. Among these isolates, 1,2-bis-(5- $\gamma$ -tocopheryl) ethane (**51**) was reported for the first time from natural sources. Some purified compounds were examined for their anti-inflammatory and anticancer bioactivities. The results indicated that betulinic acid (**16**) exhibited strong inhibition of superoxide anion generation with IC<sub>50</sub> value of  $0.2 \pm 0.1$   $\mu$ M, while betulinic acid (**16**) and pheophytin-a (**47**) inhibited elastase release with IC<sub>50</sub> value of  $2.7 \pm 0.3$  and  $5.3 \pm 1.0$   $\mu$ M, respectively. In addition, betulinic acid (**16**) and *epi*-glut-5(6)-en-ol (**18**) exhibited potential cytotoxicity to non-small-cell lung carcinoma (NCI-H226) and colon cancer (HCT-116) cell lines with IC<sub>50</sub> values in the range of 1.6 to 9.1  $\mu$ M.

**Keywords:** Vitaceae; anti-inflammatory; anticancer; cytotoxicity

## 1. Introduction

*Cissus assamica* L. belong to the Vitaceae family and is distributed in mainland China, Vietnam, India, Thailand, Indonesia, the southern part of Taiwan, and Lanyu Island [1]. Traditional Chinese medical literature records that the stem of *C. assamica* can activate the circulation to remove blood stasis and treat bruises, fractures, and rheumatoid arthritis [2]. Moreover, several active constituents, such as quinolizidine alkaloids, triterpenes, sterols, flavonoids, stilbenes, and saponins, were isolated and reported from the *Cissus* genus [3–11]. Previous biological investigations indicated that the extract of *C. sicyoides* showed moderate cytostatic activity against HEP-2 cells [12] and a significant anti-inflammatory effect [13]. In addition, studies of biological activities also showed hypoglycemic, anti-dyslipidemic, and anti-allergic effects of this genus [14–26]. However, research related to the species *C. assamica* L. is scarce. Only a few reported the effects of antagonizing the vasoconstriction

induced by endothelin-1 [22–26]. Therefore, this study aimed at the purification and identification of anticancer and anti-inflammatory principles from the stem of *C. assamica*.

## 2. Results and Discussion

### 2.1. Isolation and Characterization of Compounds

The fresh stems of *C. assamica* L. were extracted with methanol and refluxed for 8 h. The filtrate was concentrated under reduced pressure to yield a dark brown syrup. The crude extract was suspended in water and then partitioned with chloroform and *n*-butanol successively to afford chloroform, *n*-butanol, and water layers, respectively. Purification of the three layers by column chromatography yielded a mixture of  $\beta$ -sitosterol (1) and stigmasterol (2) [27],  $\beta$ -sitosteryl glucoside (3) [28], a mixture of  $3\beta$ -hydroxyl stigmaster-5-en-7-one (4) and  $3\beta$ -hydroxystigmaster-5, 22-dien-7-one (5) [29], a mixture of  $\beta$ -sitostenone (6) [30] and stigmaster-4,22-dien-3-one (7) [31],  $6\beta$ -hydroxy- $\beta$ -sitostenone (8) [32], ergosterol peroxide (9) [33], 3,5,7,4'-tetramethoxyflavone (10) [34], 3',4',3,6,7-pentamethoxyflavone (11) [35], 3',4',5,6,7-pentamethoxyflavone (12) [35], 4',5,6,7-tetramethoxyflavone (13) [36], a mixture of oleanolic acid (14) [30] and ursolic acid (15) [28], betulinic acid (16) [37], friedelin (17) [38], *epi*-glut-5(6)-en-ol (18) [39], taraxerol (19) [9], *epi*-friedelinol (20) [40], glutinone (21) [41], lup-28-al-20(29)-en-3-ol (22) [42], a mixture of  $\alpha$ -amyrin (23) and  $\beta$ -amyrin (24) [43], bergenin (25) [44], *p*-hydroxybenzaldehyde (26) [45], vanillin (27) [30], methyl gallate (28) [46], gallic acid (29) [47], 4-methoxybenzoic acid (30) [48], vanillic acid (31) [30], a mixture of 4-hydroxy-*trans*-cinnamic acid methyl ester (32) and 4-hydroxy-*cis*-cinnamic acid methyl ester (33) [49], a mixture of octadecyl-*trans*-ferulate (34) and octadecyl-*cis*-ferulate (35) [50], 1-(4-methoxy-phenyl)undecan-1-one (36) [51], 3-hydroxy-4-methoxybenzoic acid (37) [52], hexadecyl ferulate (38) [45], 2-hydroxybenzoquinone (39) [53], 2,6-dimethoxybenzoquinone (40) [49], 3,3',4-tri-*O*-methyl-ellagic acid (41) [54], 3,3',4,4'-tetra-*O*-methylellagic acid (42) [55], methyl pheophorbide-a (43) [49], a mixture of methyl-21-hydroxy-(21S)-pheophorbide-a (44) and methyl-21-hydroxy-(21R)-pheophorbide-a (45) [49], methyl-21-hydroxyl-(21S)-pheophorbide-b (46) [49], pheophytin-a (47) [49],  $\alpha$ -tocopherol (48) [56], tocopherol trimer IVa (49) [57], tocopherol trimer IVb (50) [57], 1,2-bis-(5- $\gamma$ -tocopheryl)ethane (51) [58],  $\alpha$ -tocospirol B (52) [59], 5,6-dimethoxy-3-methyl-2-cyclohexa-2,5-dien-1,4-dione (53) [60], 3-methyl-8-hydroxy-3,4-dihydroisocoumarin (54) [61], and methyl linoleate (55) [62], respectively. Among them, 1,2-bis-(5- $\gamma$ -tocopheryl)ethane (51) (Figure 1) is reported from natural sources for the first time.




Figure 1. Structures of compounds 16, 18, 47 and 51.

## 2.2. Structural Elucidation of Compound 51

1,2-Bis-(5- $\gamma$ -tocopheryl)ethane (**51**) was isolated as a light yellow syrup. Its UV spectrum had an absorption maximum at 294 nm. The IR spectrum suggested the presence of hydroxyl ( $3444\text{ cm}^{-1}$ ) and an aromatic conjugated double bond ( $1458$  and  $1377\text{ cm}^{-1}$ ). The  $^{13}\text{C}$ -NMR and DEPT spectra exhibited a benzene ring partial structure that has two oxygenated substituents at  $\delta$  117.0 (s), 122.1 (s), 123.4 (s), 124.1 (s), 145.5 (s), and 146.3 (s). The  $^1\text{H}$ -NMR spectrum of **51** exhibited signals for two methyl and one methylene groups attached to a benzene ring at  $\delta$  2.13, 2.18, and 2.73. Comparing all the  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR spectral signals carefully, the structure of **51** was similar to that of  $\alpha$ -tocopherol (**48**) [56]. It indicated that they are very closely related analogues, differing only in the presence of a methylene group ( $\delta_{\text{H}}$  2.73,  $\delta_{\text{C}}$  26.7) in **51**, instead of the methyl group ( $\delta_{\text{H}}$  2.17,  $\delta_{\text{C}}$  11.2) found in **48** (Table 1). To establish the structure of **51**, 2D NMR including correlation spectroscopy (COSY), nuclear Overhauser enhancement spectroscopy (NOESY), heteronuclear multiple quantum correlation (HMQC), and heteronuclear multiple bond correlation (HMBC) experiments were conducted. In the HMBC experiment, the correlations observed for H-5a ( $\delta_{\text{H}}$  2.18)/C-4, C-5, C-6 and H-6a ( $\delta_{\text{H}}$  2.13)/C-1, C-5, C-6 indicate that two methyl groups are located in the ortho position on the benzene ring. Moreover, the correlation of the methylene proton at  $\delta_{\text{H}}$  2.73 with C-3 in HMBC spectrum suggests that the location C-3a in the dimerization of  $\alpha$ -tocopherol forms the dimer **51**. Conclusively, the structure of **51** was assigned as 1,2-bis-(5- $\gamma$ -tocopheryl)ethane, which had been reported by synthesis [58], but is reported from natural sources for the first time. The NMR spectra are presented Figures S1–S6.

**Table 1.**  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR spectra data of **48** and **51** ( $\text{CDCl}_3$ , 400 MHz).

Position	48		51	
	$\delta_{\text{H}}$ (mult., $J$ in Hz)	$\delta_{\text{C}}$	$\delta_{\text{H}}$ (mult., $J$ in Hz)	$\delta_{\text{C}}$
1		145.5		146.3
2		117.2		117.0
3		118.5		123.4
4		144.5		145.5
5		121.1		122.1
6		122.6		124.1
7	2.64 (t, 4.5)	21.0	2.74 (m)	21.7
8	1.79 (m)	31.5	1.83 (m)	32.3
9		74.5		75.3
10	1.56 (m)	39.8	1.56 (m)	40.7
11	1.54 (m)	22.6	1.54 (m)	21.3
12	1.26–1.25 (m)	37.4	1.28–1.25 (m)	38.2
13	1.31 (d, 7.4)	32.7	1.32 (d, 7.2)	33.4
14	1.26–1.25 (m)	37.2	1.28–1.25 (m)	37.9
15	1.26–1.25 (m)	24.8	1.28–1.25 (m)	25.5
16	1.26–1.25 (m)	37.5	1.28–1.25 (m)	38.2
17	1.31 (d, 7.4)	32.8	1.32 (d, 7.2)	33.5
18	1.16–1.13 (m)	37.4	1.16–1.13 (m)	38.2
19	1.16–1.13 (m)	25.1	1.16–1.13 (m)	25.2
20	1.16–1.13 (m)	39.4	1.16–1.13 (m)	40.1
21	1.52 (m)	27.9	1.52 (m)	28.7
22	0.91 (d, 6.4)	23.7	0.86 (d, 7.2)	23.4
3a	2.17 (s)	11.2	2.73 (s)	26.7
5a	2.22 (s)	12.8	2.18 (s)	12.8
6a	2.19 (s)	11.8	2.13 (s)	12.6
9a	1.28 (s)	24.4	1.24 (s)	24.5
13a	0.90 (d, 7.4)	20.3	0.85 (d, 7.2)	20.3
17a	0.89 (d, 7.4)	20.7	0.83 (d, 7.2)	20.5
21a	0.93 (d, 6.5)	22.7	0.87 (d, 7.2)	23.3
OH	4.25 (s)		5.41 (s)	

### 2.3. Anti-Inflammatory Activity

Neutrophils are the most abundant white blood cells and participate in the development of the inflammatory reactions in human body; they are important factors in the immune defense against various diseases. Some cytotoxins—for example, the superoxide anion radical, bioactive lipids, granule proteases, and elastase—can be secreted when the different stimuli activate neutrophils. Moreover, they are also major contributors to tissue destruction in chronic inflammatory diseases. It has been proposed that inhibiting neutrophil activation is a method of enhancing inflammatory disorders [63–66]. Most of the purified compounds in this study were inspected for the inhibition of elastase release and superoxide anion generation by human neutrophils in response to *N*-formyl-L-methionyl-phenylalanine/cytochalasin B (fMLP/CB). Only compound **16** (Figure 1) displayed significant inhibition of superoxide anion generation, with an  $IC_{50}$  value of  $0.2 \pm 0.1 \mu M$  (Table 2). In addition, compounds **16** and **47** also exhibited an inhibitory effect on elastase release with an  $IC_{50}$  value of  $2.7 \pm 0.3$  and  $5.3 \pm 1.0 \mu M$ , respectively (Table 2). The inhibitory effects of all the tested compounds on superoxide anion generation and elastase release by human neutrophils in response to fMLP/CB are presented in Table S1. The cytotoxicity of compounds **16**, **47**, and LY294002 (a PI3K inhibitor, as a positive control) was examined in human neutrophils using an LDH release assay (Figure S7). All these compounds did not induce LDH release, suggesting that the inhibitory effects did not result from cytotoxicity in human neutrophils.

**Table 2.** Inhibitory effects of isolated compounds on superoxide anion generation and elastase release by human neutrophils in response to fMLP/CB.

Compound	Superoxide Anion Generation	Elastase Release
	$IC_{50}$ ( $\mu M$ ) <sup>a</sup>	$IC_{50}$ ( $\mu M$ )
<b>16</b>	$0.2 \pm 0.1$ ***	$2.7 \pm 0.3$ ***
<b>47</b>	>10	$5.3 \pm 1.0$ ***
LY294002 <sup>b</sup>	$0.4 \pm 0.1$ ***	$1.5 \pm 0.3$ ***

Results are presented as mean  $\pm$  S.D. ( $n = 3\sim 4$ ). \*\*\*  $p < 0.001$  compared with the control (DMSO).<sup>a</sup> Concentration necessary for 50% inhibition ( $IC_{50}$ ).<sup>b</sup> A phosphatidylinositol-3-kinase inhibitor was used as a positive control.

### 2.4. Cytotoxicity

In order to evaluate the growth inhibitory activity of the purified compounds against cancer cells, this study selected three different cell lines from malignant tumors including human nasopharyngeal carcinoma (NPC-TW01), non-small-cell lung carcinoma (NCI-H226), and colon cancer cell lines (HCT116). The results showed that betulinic acid (**16**) and *epi*-glut-5(6)-en-ol (**18**) (Figure 1) exhibited significant cytotoxicity with  $IC_{50}$  values ranged from 1.6 to 9.1  $\mu M$  (Table 3). Moreover, betulinic acid (**16**) exhibited powerful inhibitory activity against NCI-H226 and HCT116 with  $IC_{50}$  values of 2.0 and 1.6  $\mu M$ , respectively. Our study suggested the stem extracts of *C. assamica* and the purified compounds are potential candidates for the development of anti-cancer drugs. The preliminary growth inhibitory activity of all the tested compounds is presented in Table S2.

**Table 3.** Cytotoxicity of compounds **16**, **18**, **20**, **21**, **41** and **52**.

Compounds	Cell Lines	
	NCI-H226	HCT-116
	$IC_{50}$ ( $\mu M$ )	$IC_{50}$ ( $\mu M$ )
<b>16</b>	2.0	1.6
<b>18</b>	9.1	6.0
<b>20</b>	15.8	16.7
<b>21</b>	38.0	24.0
<b>41</b>	31.6	30.3
<b>52</b>	>50	39.4

### 3. Materials and Methods

#### 3.1. General Information

UV spectra were obtained with a Hitachi UV-3210 and UV-3010 spectrophotometer (Hitachi, Tokyo, Japan), and IR spectra were measured with a Shimadzu FTIR Prestige-21 spectrometer (Shimadzu, Kyoto, Japan). Optical rotations were measured with a HORIBA SEPA-300 digital polarimeter in a 0.5 dm cell (Horiba, Kyoto, Japan). The ESIMS and HRESIMS were taken on a Bruker Daltonics APEX II 30e spectrometer (Bruker, Billerica, MA, USA).  $^1\text{H}$ - and  $^{13}\text{C}$ -NMR spectra were measured using Bruker Avance-300, AMX-400, and AV-500 spectrometers (Bruker, Billerica, MA, USA) with TMS as the internal reference, and chemical shifts are expressed in  $\delta$  (ppm). Silica gel (70–230 and 230–400 mesh; Merck, Darmstadt, Germany) and Spherical C18 100 Å reversed phase silica gel (RP-18; particle size 20–40  $\mu\text{m}$ ; Silicycle, Quebec City, QC, Canada) were used for column chromatography (CC), and silica gel 60 F<sub>254</sub> and RP-18 F<sub>254S</sub> thin-layer chromatography (TLC) plates (Merck, Darmstadt, Germany) were used for preparative TLC, respectively.

#### 3.2. Materials

The fresh stems of *C. assamica* L. were collected from Taitung Hsien, Taiwan, in October 2009 and verified by Prof. Chang-Sheng Kuoh (Department of Biology, National Cheng Kung University, Tainan, Taiwan). A voucher specimen (TSWu 20091016) has been deposited in the Herbarium of School of Pharmacy, National Cheng Kung University, Tainan, Taiwan.

#### 3.3. Extraction and Isolation

The fresh stems of *C. assamica* L. (15 kg) were extracted with methanol (15  $\times$  20 L) and refluxed for 8 h. The filtrate was evaporated under reduced pressure to yield a dark brown syrup (418 g). The residue was suspended in water and then partitioned with chloroform (5  $\times$  2 L) and *n*-butanol (5  $\times$  2 L) successively to afford chloroform (63 g), *n*-butanol (145 g) and water (210 g) soluble fractions respectively.

The chloroform soluble extracts were fractionated via silica gel column chromatography eluting with *n*-hexane/acetone (9:1) to afford seven fractions, on the basis of TLC monitoring. Fraction 1 was subjected to silica gel column chromatography eluted with *n*-hexane/acetone (79:1) to yield a mixture of  $\beta$ -sitosterol (**1**) and stigmasterol (**2**) (3.1 g), 3,5,7,4'-tetramethoxyflavone (**10**, 2.9 mg), 3',4',3,6,7-pentamethoxyflavone (**11**, 12.2 mg), 3',4',5,6,7-pentamethoxyflavone (**12**, 6.1 mg), 4',5,6,7-tetramethoxyflavone (**13**, 3.1 mg), friedelin (**17**, 1.8 g), taraxerol (**19**, 3.9 mg), glutinone (**21**, 3.2 mg) and methyl linoleate (**55**, 20.7 mg).

Purification of fraction 2 by column chromatography with silica gel was eluted by a gradient of benzene/ethyl acetate (79:1) to afford *epi*-glut-5(6)-en-ol (**18**, 23.2 mg),  $\alpha$ -tocopherol (**48**, 200 mg), tocopherol trimer IVa (**49**, 24.3 mg), tocopherol trimer IVb (**50**, 28.1 mg), 1,2-bis-(5- $\gamma$ -tocopheryl)-ethane (**51**, 15.4 mg),  $\alpha$ -tocospirol B (**52**, 6.1 mg) and 5,6-dimethoxy-3-methyl-2-cyclohexa-2,5-dien-1,4-dione (**53**, 52.2 mg).

Separation of fraction 3 by column chromatography with silica gel eluted by *n*-hexane/ethyl acetate (9:1) yielded a mixture of 3 $\beta$ -hydroxystigmast-5-en-7-one (**4**) and 3 $\beta$ -hydroxystigmast-5,22-dien-7-one (**5**, 4.5 mg), a mixture of  $\beta$ -sitostenone (**6**) and stigmasta-4,22-dien-3-one (**7**, 13.7 mg), 6 $\beta$ -hydroxy- $\beta$ -sitostenone (**8**, 16.9 mg), ergosterol peroxide (**9**, 35 mg), *epi*-friedelinol (**20**, 200 mg), lup-28-al-20(29)-en-3-ol (**22**, 3.2 mg), a mixture of  $\alpha$ -amyrin (**23**) and  $\beta$ -amyrin (**24**, 60 mg), a mixture of 4-hydroxy-*trans*-cinnamic acid methyl ester (**32**) and 4-hydroxy-*cis*-cinnamic acid methyl ester (**33**, 190 mg), a mixture of octadecyl-*trans*-ferulate (**34**) and octadecyl-*cis*-ferulate (**35**, 45.3 mg), hexadecyl ferulate (**38**, 20.7 mg) and 3-methyl-8-hydroxy-3,4-dihydroisocoumarin (**55**, 3.5 mg).

Fraction 4 was chromatographed over silica gel eluted with a benzene/acetone gradient (49:1) to give a mixture of oleanolic acid (**14**) and ursolic acid (**15**, 49.6 mg), betulinic acid (**16**, 63.6 mg), 4-methoxybenzoic acid (**30**, 4.7 mg), 1-(4-methoxyphenyl)undecan-1-one (**36**, 2.3 mg) and pheophytin-a (**47**, 11.2 mg).

Purification of fraction 5 by column chromatography with silica gel was eluted by a gradient of chloroform/acetone (49:1) to afford 2-hydroxybenzoquinone (**39**, 3.5 mg), methyl pheophorbide-a (**43**, 3.1 mg), a mixture of methyl-21-hydroxy-(21S)-pheophorbide-a (**44**) and methyl-21-hydroxy-(21R)-pheophorbide-a (**45**, 3.5 mg).

Separation of fraction 6 by column chromatography with a silica gel eluted by chloroform/acetone (49:1) yielded *p*-hydroxybenzaldehyde (**26**, 4.0 mg), 3,3',4-tri-*O*-methylellagic acid (**41**, 37.7 mg), 3,3',4,4'-tetra-*O*-methylellagic acid (**42**, 1.5 mg) and methyl-21-hydroxy-(21S)-pheophorbide-b (**46**, 3.6 mg).

Fraction 7 was subjected to silica gel column chromatography eluted with chloroform/methanol (49:1) to yield  $\beta$ -sitosterol glucoside (**3**, 700 mg), vanillin (**27**, 7.8 mg), vanillic acid (**31**, 1.7 mg), 3-hydroxy-4-methoxybenzoic acid (**37**, 3.2 mg), 2, 6-dimethoxybenzoquinone (**40**) (3.5 mg).

The *n*-butanol layer was subjected directly to Diaion HP-20 column chromatography, eluted with water containing increasing proportions of methanol, to give six fractions. Fraction 1 was chromatographed over Sephadex LH-20 eluted with gradient of water/methanol to give gallic acid (**29**, 600 mg). Fraction 2 was chromatographed on Sephadex LH-20 eluted with gradient of water/methanol to afford bergenin (**25**, 6.2 g). Fraction 4 was chromatographed on Sephadex LH-20 with water/methanol to give methyl gallate (**28**, 32.1 mg).

1,2-Bis-(5- $\gamma$ -tocopheryl)ethane (**51**): light yellow syrup; UV  $\lambda_{\max}$  (MeOH) nm (log  $\epsilon$ ) 294; IR (KBr)  $\nu_{\max}$  cm<sup>-1</sup> 3444, 2920, 2850, 1458, 1377, 1257, 1087; <sup>1</sup>H- and <sup>13</sup>C-NMR data, see Table 1.

### 3.4. Anti-Inflammatory Bioactivity Examination

#### 3.4.1. Preparation of Human Neutrophils

Human neutrophils study was approved by Chang Gung Memorial Hospital Institutional Review Board, Taoyuan, Taiwan. It was conducted according to the Declaration of Helsinki. Blood was obtained from healthy donors (20–32 years old) who provided written informed consent before blood was drawn. Briefly, neutrophils were isolated by dextran sedimentation, Ficoll-Hypaque gradient centrifugation, and hypotonic lysis of the erythrocytes [67].

#### 3.4.2. Measurement of Superoxide Anion Generation and Elastase Release

The superoxide anion generation and elastase release were measured using the reduction of ferricytochrome *c* and elastase substrate, methoxysuccinyl-Ala-Ala-Pro-Val-*p*-nitroanilide, respectively, as described previously [68–70]. Human neutrophils were suspended in HBSS containing ferricytochrome *c* (0.6 mg/mL) or elastase substrate (100  $\mu$ M) at 37 °C and treated with DMSO or tested compounds for 5 min. The cells were then activated using fMLF (0.1  $\mu$ M)/cytochalasin B (CB, 1  $\mu$ g/mL for superoxide generation and 0.5  $\mu$ g/mL for elastase release) and the change of absorbance was continually measured at 550 nm and 405 nm by a spectrophotometer (U-3010, Hitachi) to determine the superoxide anion generation and elastase release, respectively.

#### 3.4.3. Detection of Cytotoxicity

Human neutrophils were treated with DMSO or tested compounds and incubated at 37 °C for 15 min. The supernatant was assayed to detect the released LDH using CytoTox 96 non-radioactive cytotoxicity assay (Promega, Madison, WI, USA). The results are presented in Figure S7.

### 3.5. Determination of Anticancer Bioactivity

#### 3.5.1. Cell Lines

Human cancer cell lines, non-small cell lung carcinoma (NCI-H226) and colon cancer cell line (HCT116) were obtained from the American Type Culture Collection (Rockville, MD, USA). A nasopharyngeal carcinoma (NPC-TW01) cell line was purchased from Food Industry Research and

Development Institute (Hsinchu, Taiwan). Tumor cells were maintained in proper medium supplemented with 10% fetal bovine serum (FBS) at 37 °C in a humidified atmosphere of 5% CO<sub>2</sub>.

### 3.5.2. Growth Inhibition Assay

The evaluation of cell growth and survival was carried out according to Hansen et al. [71] with some modifications.

## 4. Conclusions

In summary, 55 compounds were characterized from the fresh stems of *C. assamica*, including 14 benzenoids, 11 triterpenes, nine steroids, five tocopherols, five chlorophylls, four flavonoids, two benzoquinones, two tannins, and three other compounds. Among these isolates, 1,2-bis-(5- $\gamma$ -tocopheryl)ethane was reported for the first time from natural sources. Furthermore, the inhibitory activity on superoxide anion generation and elastase release and the cytotoxicity on three cancer cells were analyzed. The present study suggests that the stems of *C. assamica* and several compounds of its isolation could be further developed as candidates for the treatment or prevention of cancer and various inflammatory diseases. Thus, the detailed mechanism of action of these compounds appears worthy of follow-up investigation.

**Supplementary Materials:** The following are available online at [www.mdpi.com/1420-3049/23/11/2799/s1](http://www.mdpi.com/1420-3049/23/11/2799/s1), Tables S1 and S2: Anti-inflammatory and cytotoxic effects of all the tested compounds from *C. assamica*; Figures S1–S6: NMR spectra of compound **51**; Figure S7: Cytotoxicity of compounds **16**, **47** and LY294002.

**Author Contributions:** Conceptualization, T.-S.W.; Data curation, Y.-Y.C.; Investigation, C.-Y.W., H.-Y.H., P.-C.K.; Methodology, T.-L.H., S.-H.J., and P.-J.C.; Writing—original draft, Y.-Y.C., H.-Y.H.; Writing—review & editing, P.-C.K. and T.-S.W. All authors read and approved the final manuscript.

**Funding:** This study was sponsored by the Ministry of Science and Technology, Taiwan via a grant to T.-S.W. and Y.-Y.C. (NSC97-2320-B-218-001-MY3). The authors are also thankful to Chang Gung Memorial Hospital [CMRPD1B0281~3, CMRPF1D0442~3, CMRPF1F0011~3, CMRPF1F0061~3 and BMRP450 granted to T.-L.H.] for the partial financial support for the present research.

**Acknowledgments:** Authors were thankful to the Instruments Center of NCKU and the Joint Center for High Valued Instruments at NSYSU of the Ministry of Science and Technology, Taiwan for the assistance of recording NMR and MS spectra.

**Conflicts of Interest:** The authors declare no conflict of interest.

## References

1. Yang, T.Y. *Flora of Taiwan*, 2nd ed.; Editorial Committee of the Flora of Taiwan: Taipei, Taiwan, 1998; pp. 701–703.
2. Zhang, Y.Q.; Xie, Y.H.; Huang, L.P. Studies on the chemical constituents and biological activities from *Cissus L.* *Lishizhen Medicine and Materia Medica Research* **2006**, *17*, 107–114.
3. Otshudi, A.L.; Foriers, A.; Vercruysse, A.; Van, Z.A.; Lauwers, S. In vitro antimicrobial activity of six medicinal plants traditionally used for the treatment of dysentery and diarrhoea in Democratic Republic of Congo. *Phytomedicine* **2000**, *7*, 167–172.
4. Beltrame, F.L.; Sartoretto, J.L.; Bazotte, R.B.; Cuman, R.N.; Cortez, D.A.G. Phytochemical study and evaluation of the antidiabetic potential of *Cissus sicyoides* L. *Quim. Nova* **2001**, *24*, 783–785.
5. Beltrame, F.L.; Ferreira, A.G.; Cortez, D.A. Coumarin glycoside from *Cissus sicyoides*. *Nat. Prod. Lett.* **2002**, *16*, 213–216.
6. Adesanya, S.A.; Nia, R.; Martin, M.T.; Boukamcha, N.; Montagnac, A.; Pais, M. Stilbene derivatives from *Cissus quadrangularis*. *J. Nat. Prod.* **1999**, *62*, 1694–1695.
7. Bhutani, K.K.; Kapoor, R.; Atal, C.K. Two unsymmetric tetracyclic triterpenoids from *Cissus quadrangularis*. *Phytochemistry* **1984**, *23*, 407–410.
8. Gupta, M.M.; Verma, R.K. Unsymmetric tetracyclic triterpenoid from *Cissus quadrangularis*. *Phytochemistry* **1990**, *29*, 336–337.
9. Gupta, M.M.; Verma, R.K. Lipid constituents of *Cissus quadrangularis*. *Phytochemistry* **1991**, *30*, 875–878.

10. Khan, M.A.; Nabi, S.G.; Prakash, S.; Zaman, A. Pallidol, a resveratrol dimer from *Cissus pallida*. *Phytochemistry* **1986**, *25*, 1945–1948.
11. Al-Said, M.S.; Khalifa, A.S.; Al-Azizi, M.M. Flavonoids from *Cissus digitat*. *Int. J. Pharm.* **1991**, *29*, 281–283.
12. Saenz, M.T.; Garcia, M.D.; Quilez, A.; Ahumada, M.C. Cytotoxic activity of *Agave intermixta* L. (Agavaceae) and *Cissus sicyoides* L. (Vitaceae). *Phytother. Res.* **2000**, *14*, 552–554.
13. Garcia, M.D.; Quilez, A.M.; Saenz, M.T.; Martinez, D.M.E.; De, P.R. Anti-inflammatory activity of agave intermixta trel and *Cissus sicyoides* L., species used in the caribbean traditional medicine. *J. Ethnopharmacol.* **2000**, *71*, 395–400.
14. Atawodi, S.E.; Arneh, D.A.; Ibrahim, S.; Andrew, J.N.; Nzelibe, H.C.; Onyike, E.O.; Anigo, K.M.; Abu, E.A.; James, D.B.; Njoku, G.C.; Sallau, A.B. Indigenous knowledge system for treatment of trypanosomiasis in Kaduna state of Nigeria. *J. Ethnopharmacol.* **2002**, *79*, 279–282.
15. Jainu, M.; Devi, C.S.S. Effect of *Cissus quadrangularis* on gastric mucosal defensive factors in experimentally induced gastric ulcer—A comparative study with sucralfate. *J. Med. Food* **2004**, *7*, 372–376.
16. Quilez, A.M.; Saenz, M.T.; Garcia, M.D.; de la Puerta, R. Phytochemical analysis and anti-allergic study of agave intermixta trel and *Cissus sicyoides* L. *J. Pharm. Pharmacol.* **2004**, *56*, 1185–1189.
17. Viana, G.S.; Medeiros, A.; Lacerda, A.M.; Leal, L.K.; Vale, T.G.; Matos, F.J. Hypoglycemic and anti-lipemic effects of the aqueous extract from *Cissus sicyoides*. *BMC Pharmacol.* **2004**, *4*, 9–15.
18. Chidambara, M.K.N.; Vanitha, A.; Mahadeva, S.M.; Ravishankar, G.A. Antioxidant and antimicrobial activity of *Cissus quadrangularis* L. *J. Med. Food* **2003**, *6*, 99–105.
19. Pepato, M.T.; Baviera, A.M.; Vendramini, R.C.; Perez, M.P.M.S.; Kettelhut, I.C.; Brunetti, I.L. *Cissus sicyoides* in the long-term treatment of streptozotocin-diabetic rats. *Biotechnol. Appl. Biochem.* **2003**, *37*, 15–20.
20. Alzoreky, N.S.; Nakahara, K. Antibacterial activity of extracts from some edible plants commonly consumed in Asia. *Int. J. Food. Microbiol.* **2003**, *80*, 223–230.
21. Garcia, X.; Cartas, H.L.; Lorenzana, J.M.; Gijon, E. Vasoconstrictor effect of *Cissus sicyoides* on guinea Pig aortic rings. *Gen. Pharmacol.* **1997**, *29*, 457–462.
22. Mori, T.; Nishikawa, Y.; Takata, Y.; Kashuichi, N.; Ishihara, N. Effect of insulina leaf extract on development of diabetes comparison between normal, streptozotocin-induced diabetic rats and hereditary diabetic mice. *Nippon Eiyo Shokuryo Gakkaishi* **2001**, *54*, 197–203.
23. Yang, L.; Wang, F.; Liu, M.; Lu, M.; Jia, H.; Fang, X.; Li, Z. Isolation of resveratrol and its antagonistic effects on endothelin-1. *Huaxi Yaoxue Zazhi* **2000**, *15*, 81–84.
24. Wang, F.; Yang, L.; Cheng, Y.; Lu, M.; Liu, M.; Ji, X.; Jia, H. Antagonism effects of extracts of Chinese herb *Cissus assamica* and monomer CA-1201 on endothelin-1 responses. *Zhongguo Yaoxue Zazhi* **1998**, *33*, 337–340.
25. Yang, L.C.; Wang, F.; Liu, M. A study of an endothelin antagonist from a Chinese anti-snake venom medicinal herb. *J. Cardiovasc. Pharmacol.* **1998**, *31*, S249–S250.
26. Wang, F.; Yang, L.; Liu, M.; Lu, M.; Cheng, Y.; Jia, H. A primary study on antagonizing effects of anti-snake venom Chinese herb on endothelin-1 and sarafotoxin 6b. *Zhongguo Zhong Yao Za Zhi* **1997**, *22*, 620–622.
27. Shen, D.Y.; Juang, S.H.; Kuo, P.C.; Huang, G.J.; Chan, Y.Y.; Damu, A.G.; Wu, T.S. Chemical constituents from *Andrographis echinoides* and their anti-inflammatory activity. *Int. J. Mol. Sci.* **2013**, *14*, 496–514.
28. Wu, T.S.; Chan, Y.Y. Constituents of leaves of *Uncaria hirsuta* Haviland. *J. Chin. Chem. Soc.* **1994**, *41*, 209–212.
29. Kuo, Y.H.; Chu, P.H. Studies on the constituents from the bark of *Bauhinia purpurea*. *J. Chin. Chem. Soc.* **2002**, *49*, 269–274.
30. Wu, S.J.; Chan, Y.Y. Five New Iridoids from Roots of *Salvia digitaloides*. *Molecules* **2014**, *19*, 15521–15534.
31. Kuo, P.C.; Yang, M.L.; Hwang, T.L.; Lai, Y.Y.; Li, Y.C.; Thang, T.D.; Wu, T.S. Anti-inflammatory Diterpenoids from *Croton tonkinensis*. *J. Nat. Prod.* **2013**, *76*, 230–236.
32. Chang, Y.C.; Chang, F.R.; Wu, Y.C. The Constituents of *Lindera Glauca*. *J. Chin. Chem. Soc.* **2000**, *47*, 373–380.
33. Thang, T.D.; Kuo, P.C.; Hwang, T.L.; Yang, M.L.; Ngoc, T.B.; Han, T.N.; Lin, C.W.; Wu, T.S. Triterpenoids and steroids from *Ganoderma mastoporum* and their inhibitory effects on superoxide anion generation and elastase release. *Molecules* **2013**, *18*, 14285–14292.
34. Dong, H.; Gou, Y.L.; Cao, S.G.; Chen, S.X.; Sim, K.Y. Eicosenones and methylated flavonols from *Amomum koenigii*. *Phytochemistry* **1999**, *50*, 899–902.
35. Machida, K.; Osawa, K. On the flavonoid constituents from the peels of *Citrus hassaku* Hort.ex Tanaka. *Chem. Pharm. Bull.* **1989**, *37*, 1092–1094.



36. Weber, B.; Hartmann, B.; Stockigt, D.; Schreiber, K.; Roloff, M.; Bertram, H.J.; Schmidt, C.O. Liquid chromatography/mass spectrometry and liquid chromatography nuclear magnetic resonance as complementary analytical techniques for unambiguous identification of polymethoxylated flavones in residues from molecular distillation of orange peel oils (*Citrus sinensis*). *J. Agric. Food Chem.* **2006**, *54*, 274–278.
37. Chatterjee, P.; Kouzi, S.A.; Pezzuto, J.P.; Hamann, M.T. Biotransformation of the antimelanoma agent betulinic acid by *Bacillus megaterium* ATCC 13368. *Appl. Environ. Microbiol.* **2000**, *66*, 3850–3855.
38. Wu, T.S.; Chan, Y.Y.; Liou, M.J.; Lin, F.W.; Shi, L.S.; Chen, K.T. Platelet aggregation inhibitor from *Murraya euchrestifolia*. *Phytother. Res.* **1998**, *12*, S80–S82.
39. Tanabe, Y.; Sinoda, R.; Horikoshi, Y.; Takahashi, K. Studies on constituents of medicinal plants. XVI. The constituents of *Spiracea* species. *Yakugaku Zasshi* **1976**, *96*, 248–250.
40. Li, K.H.; Chang, C.R.; Chang, Y.S. Chemical components from *Triumfetta bartramia*. *J. Chin. Chem. Soc.* **1995**, *42*, 93–95.
41. Zhang, J.; Yin, Z.Q.; Cao, P.; Li, Y.B.; Duan, J.A. A new flavonol derivative from *Fagopyrum dibotrys*. *Chem. Nat. Compd.* **2008**, *44*, 701–703.
42. Hata, K.; Hori, K.; Takahashi, S. Differentiation and apoptosis-inducing activities by pentacyclic triterpenes on a mouse melanoma cell line. *J. Nat. Prod.* **2009**, *65*, 645–648.
43. Bolleddula, J.; Mulabagal, V.; Yanjun, Z.; David, L.D.; Muraleedharan, G.N. Impact of alkyl esters of caffeic and ferulic acids on tumor cell proliferation cyclooxygenase enzyme and lipid peroxidation. *J. Agric. Food Chem.* **2006**, *54*, 5375–5381.
44. Xie, Y.H.; Zhang, Y.Q.; Deng, P.; Yu, W.S. Determination of bergenin in *Cissus assamica* by HPLC. *Shizhen Guoyi Guoyao* **2009**, *20*, 1086–1087.
45. Chiang, C.Y.; Leu, Y.L.; Chan, Y.Y.; Wu, T.S. Sodium aristolochates from the flowers and fruits of *Aristolochia zollingeriana*. *J. Chin. Chem. Soc.* **1998**, *45*, 93–97.
46. Choi, S.E.; Yoon, J.H.; Choi, H.K.; Lee, M.W. Phenolic compounds from the root of *Phragmites communis*. *Chem. Nat. Compd.* **2009**, *45*, 893–895.
47. Jun, X.L.; Duo, L.D.; Yan, P.S. Diversity of chemical constituents from *Saxifraga montana* H. *J. Chin. Chem. Soc.* **2008**, *55*, 863–870.
48. Cui, L.Q.; Liu, K.; Zhang, C. Effective oxidation of benzylic and alkane C–H bonds catalyzed by sodium O-iodobenzenesulfonate with oxone as a terminal oxidant under phase-transfer conditions. *Org. Biomol. Chem.* **2011**, *9*, 2258–2265.
49. Wu, T.S.; Tsanga, Z.J.; Wu, P.L.; Lin, F.W.; Li, C.Y.; Temg, C.M.; Lee, K.H. New constituents and antiplatelet aggregation and anti-HIV principles of *Artemisia capillaris*. *Bioorg. Med. Chem.* **2001**, *9*, 77–83.
50. Wei, H.; Wen, D.X.; Liu, X.S.; Tang, R.J. Constituents in petroleum ether and ethyl acetate extract fractions of *Dracaena cochinchinensis*. (Lour.) *Zhong Guo Zhong Yao Za Zhi* **1998**, *23*, 616–618.
51. Loupy, A.; Chatti, S.; Delamare, S.; Lee, D.-Y.; Chung, J.-H.; Jun, C.-H. Solvent-free chelation-assisted hydroacylation of olefins rhodium(I) catalyst under microwave irradiation. *J. Chem. Soc.* **2002**, *10*, 1280–1285.
52. Ding, H.Y.; Lin, H.C.; Teng, C.M.; Wu, Y.C. Phytochemical and pharmacological studies on Chinese *Paeonia* species. *J. Chin. Chem. Soc.* **2000**, *47*, 381–388.
53. Magdziak, D.; Rodriguez, A.A.; Van, D.W.; Ryan, W.; Pettus, T.R.R. Regioselective oxidation of phenols to O-quinones with O-iodoxybenzoic Acid (IBX). *Org. Lett.* **2002**, *4*, 285–288.
54. Gao, X.; Wu, J.; Zou, W.; Dai, Y. Two ellagic acids isolated from roots of *Sanguisorba officinalis* L. promote hematopoietic progenitor cell proliferation and megakaryocyte differentiation. *Molecules* **2014**, *19*, 5448–5458.
55. Reitze, J.D.; Przewloka, S.R.; Shearer, B.J. The further chemistry of ellagic acid: I. synthesis of tetramethylellagic acid and associated polymer precursors. *Holzforschung* **2005**, *55*, 171–175.
56. Almeida, E.R.D.; Rafael, K.R.D.O.; Couto, G.B.L.; Ishigmi, A.B. Anxiolytic and anticonvulsant effects on mice of flavonoids, linalool, and  $\alpha$ -tocopherol presents in the extract of leaves of *Cissus sicyoides* L. *J. Biomed. Biotechnol.* **2009**, *1*, 1–6.
57. Lie, C.R.; Jiau, C.H.; Chiu, M.C. Cerebrosides and tocopherol trimers from the seeds of *Euryale ferox*. *J. Nat. Prod.* **2007**, *70*, 1214–1217.

58. Rosenau, T.; Kloser, E.; Gille, L.; Mazzini, F.; Netscher, T. Vitamin E chemistry. studies into initial oxidation intermediates of  $\alpha$ -tocopherol: disproving the involvement of 5a-C-centered chromanol methide radicals. *J. Org. Chem.* **2007**, *72*, 3268–3281.
59. Chiang, Y.M.; Kuo, Y.H. Two novel  $\alpha$ -tocopheroids from the aerial roots of *Ficus microcarpa*. *Tetrahedron Lett.* **2003**, *44*, 5125–5128.
60. Lipshutz, B.H.; Butler, T.; Lower, A. Controlling regiochemistry in negishi carboaluminations fine tuning the ligand on zirconium. *J. Am. Chem. Soc.* **2006**, *128*, 15396–15398.
61. Zeng, Z.X.; Ma, W.H.; Li, Y.L.; Han, T.; Zheng, C.J.; Qin, L.P. Two new diterpenes from *Solidago canadensis*. *Helv. Chim. Acta.* **2012**, *95*, 1121–1125.
62. Zeng, Z.X.; Li, Y.L.; Dong, L.L.; Fan, G.X.; Fei, D.Q. Chemical constituents of the roots of *Ligularia lapathifolia*. *Chem. Nat. Compd.* **2015**, *51*, 375–377.
63. Witko-Sarsat, V.; Rieu, P.; Descamps-Latscha, B.; Lesavre, P.; Halbwachs-Mecarelli, L. Neutrophils: Molecules, functions and pathophysiological aspects. *Lab. Investig.* **2000**, *80*, 617–653.
64. Borregaard, N. The human neutrophil. Function and dysfunction. *Eur. J. Haematol.* **1998**, *41*, 401–413.
65. Roos, D.; van Bruggen, R.; Meischl, C. Oxidative killing of microbes by neutrophils. *Microbes Infect.* **2003**, *5*, 1307–1315.
66. Faurschou, M.; Borregaard, N. Neutrophil granules and secretory vesicles in inflammation. *Microbes Infect.* **2003**, *5*, 1317–1327.
67. Chen, P.J.; Wang, Y.L.; Kuo, L.M.; Lin, C.F.; Chen, C.Y.; Tsai, Y.F.; Shen, J.J.; Hwang, T.L. Honokiol suppresses TNF- $\alpha$ -induced neutrophil adhesion on cerebral endothelial cells by disrupting polyubiquitination and degradation of IkappaB $\alpha$ . *Sci. Rep.* **2016**, *6*, 26554.
68. Yang, S.C.; Chung, P.J.; Ho, C.M.; Kuo, C.Y.; Hung, M.F.; Huang, Y.T.; Chang, W.Y.; Chang, Y.W.; Chan, K.H.; Hwang, T.L. Propofol inhibits superoxide production, elastase release, and chemotaxis in formyl peptide-activated human neutrophils by blocking formyl peptide receptor 1. *J. Immunol.* **2013**, *190*, 6511–6519.
69. Babior, B.M.; Kipnes, R.S.; Curnutte, J.T. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. *J. Clin. Investig.* **1973**, *52*, 741–744.
70. Hwang, T.L.; Li, G.L.; Lan, Y.H.; Chia, Y.C.; Shieh, P.W.; Wu, Y.H.; Wu, Y.C. Potent inhibition of superoxide anion production in activated human neutrophils by isopedicin, a bioactive component of the Chinese medicinal herb *Fissistigma oldhamii*. *Free Radic. Biol. Med.* **2009**, *46*, 520–528.
71. Hansen, M.B.; Nielsen, S.E.; Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. *J. Immunol. Methods* **1989**, *119*, 203–210.

**Sample Availability:** Samples of all the isolated compounds are available from the authors.



© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).